Morphine Drugs Market (By Dosage Form: Injection, Oral; By Application: Pain Management; By Distribution Channel; By End-use) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

The global morphine drugs market size was surpassed at USD 23.88 billion in 2023 and is expected to hit around USD 37.87 billion by 2033, growing at a CAGR of 4.72% from 2024 to 2033. The morphine drugs market is driven by an increasing prevalence of chronic pain conditions, expanding geriatric population, increasing surgical procedures, growing awareness and acceptance of opioid therapy, and advancements in drug formulations.

Morphine Drugs Market Size 2024 to 2033

Key Pointers

  • North America led the market with the largest market share in 2023.
  • By Dosage Form, the injection segment held the largest revenue share in 2023.
  • By Application, the pain management segment captured the highest revenue share in 2023.
  • By Distribution Channel, the hospital pharmacies segment generated the maximum market share in 2023.
  • By End-use, the hospitals & clinics segment held the largest revenue share in 2023.          

Morphine Drugs Market Overview

The morphine drugs market encompasses a significant segment within the pharmaceutical industry, focusing on medications derived from the opium poppy plant. Morphine, a potent opioid analgesic, is widely used for pain management in various medical settings, including post-surgical care, palliative care, and treatment of chronic pain conditions.

Morphine Drugs Market Growth

The growth of the morphine drugs market is fueled by several key factors. Firstly, the increasing prevalence of chronic pain conditions worldwide, coupled with an aging population, is driving the demand for effective pain management solutions. Additionally, the rising number of surgical procedures, particularly in areas such as orthopedics and oncology, contributes to the market's growth. Furthermore, the growing awareness among healthcare professionals regarding the efficacy of morphine in pain management, along with advancements in drug delivery technologies, is expanding the market's reach. Moreover, strategic initiatives by key market players, including product launches and partnerships, are further stimulating market growth. Despite challenges such as concerns about opioid addiction and regulatory constraints, the morphine drugs market is poised for significant expansion in the coming years, driven by the increasing need for safe and efficient pain relief options.

Morphine Drugs Market Trends:

  • Increasing Demand: The morphine drugs market is witnessing a steady increase in demand due to the rising prevalence of chronic pain conditions such as cancer, arthritis, and post-surgical pain. This demand is expected to continue growing as the global population ages and instances of chronic diseases rise.
  • Advancements in Formulations: Pharmaceutical companies are constantly innovating to develop new formulations of morphine drugs, including extended-release formulations, transdermal patches, and combination therapies. These advancements aim to enhance efficacy, reduce side effects, and improve patient compliance.
  • Expanding Applications: Morphine drugs are no longer limited to pain management in cancer patients. They are increasingly being prescribed for various acute and chronic pain conditions, including neuropathic pain, back pain, and musculoskeletal pain, thereby expanding the market reach.
  • Growing Awareness and Acceptance: There is a growing awareness among healthcare professionals and patients about the benefits of morphine drugs in pain management. This increased awareness, coupled with the acceptance of opioid therapy as a standard treatment option, is contributing to the market growth.
  • Market Consolidation: The morphine drugs market is witnessing consolidation as pharmaceutical companies engage in mergers, acquisitions, and strategic partnerships to strengthen their product portfolios and expand their market presence. This consolidation is expected to intensify competition and drive innovation in the market.
  • Focus on Personalized Medicine: There is a growing trend towards personalized medicine, wherein morphine drug therapy is tailored to individual patient characteristics such as genetic makeup, metabolism, and pain sensitivity. This approach aims to optimize treatment outcomes and minimize the risk of adverse effects.

Dosage Form Insights

The morphine drug market is categorized based on dosage forms, including injection, oral, and other formulations. As of 2023, the injection segment dominated the market. These injections are primarily employed to relieve moderate to severe pain, and they can also be used as part of anesthesia before or during surgical procedures. Notable brands in this segment include Astramorph PF, Infumorph, and Duramorph.

Application Insights

The market is segmented based on application into pain management, diarrhea suppression, cold and cough suppression, and other uses. In 2023, the pain management segment captured the largest revenue share. This can be attributed to the extensive utilization of morphine for pain relief purposes. It is employed to address or alleviate pain stemming from diverse conditions such as surgical procedures, labor pain, cancer-related pain, and significant trauma such as accidents.

Distribution Channel Insights

The market is segmented according to distribution channels, including retail pharmacies, hospital pharmacies, online pharmacies, and others. In 2023, hospital pharmacies dominated the market share. Hospital pharmacies are situated within healthcare facilities, facilitating administration and monitoring under the direct supervision of healthcare professionals. The increasing incidence of accidents and trauma, combined with the widespread use of morphine for surgical procedures and pain management, is projected to drive growth in this segment throughout the forecast period.

End-Use Insights

The morphine drug market is segmented based on end use into hospitals & clinics, ambulatory surgical centers, and others. As of 2023, the hospitals & clinics segment held the largest revenue share. It's important to note that morphine may lead to side effects such as overdose, headache, dizziness, lightheadedness, and mood changes; hence, it is recommended to use it under the supervision of a doctor.

Hospitals and clinics utilize morphine extensively, particularly for effective pain management in patients recovering from surgery, coping with severe injuries, or dealing with acute medical conditions. Additionally, a study published by Science Direct in 2019 highlights the use of opioids like morphine as sedatives in the Intensive Care Unit (ICU).

Regional Insights

In 2023, North America emerged as the dominant market. The presence of well-established players is projected to bolster market growth further. Moreover, the pharmaceutical sector's high demand and increasing occurrences of musculoskeletal diseases are anticipated to drive regional expansion throughout the forecast period.

Morphine Drugs Market Share, By Region, 2023 (%)

According to a factsheet released by the Department of Justice/Drug Enforcement Administration in April 2020, morphine derived from opium is directly utilized for pharmaceutical purposes in the U.S. Consequently, the utilization of morphine in the pharmaceutical industry is expected to drive market demand in the region over the forecast period.

Morphine Drugs Market Key Companies

  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Verve Health Care Ltd.
  • Mallinckrodt Pharmaceuticals
  • Purdue Pharma
  • Qinghai Pharmaceuticals
  • AbbVie Inc.

Morphine Drugs Market Segmentations:

By Dosage Form

  • Injection
  • Oral
  • Other

By Application

  • Pain Management
  • Diarrhea Suppressant
  • Cold & Cough Suppressant
  • Others

By Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
  • Others

By End-use

  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Others

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa (MEA)

Frequently Asked Questions

The global morphine drugs market size was reached at USD 23.88 billion in 2023 and it is projected to hit around USD 37.87 billion by 2033.

The global morphine drugs market is growing at a compound annual growth rate (CAGR) of 4.72% from 2024 to 2033.

The North America region has accounted for the largest morphine drugs market share in 2023.

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Morphine Drugs Market 

5.1. COVID-19 Landscape: Morphine Drugs Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Morphine Drugs Market, By Dosage Form

8.1. Morphine Drugs Market, by Dosage Form, 2024-2033

8.1.1. Injection

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Oral

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Other

8.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Morphine Drugs Market, By Application

9.1. Morphine Drugs Market, by Application, 2024-2033

9.1.1. Pain Management

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Diarrhea Suppressant

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Cold & Cough Suppressant

9.1.3.1. Market Revenue and Forecast (2021-2033)

9.1.4. Others

9.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Morphine Drugs Market, By Distribution Channel 

10.1. Morphine Drugs Market, by Distribution Channel, 2024-2033

10.1.1. Retail Pharmacies

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Hospital Pharmacies

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. Online Pharmacies

10.1.3.1. Market Revenue and Forecast (2021-2033)

10.1.4. Others

10.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global Morphine Drugs Market, By End-use 

11.1. Morphine Drugs Market, by End-use, 2024-2033

11.1.1. Hospitals & Clinics

11.1.1.1. Market Revenue and Forecast (2021-2033)

11.1.2. Ambulatory Surgical Centers

11.1.2.1. Market Revenue and Forecast (2021-2033)

11.1.3. Others

11.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 12. Global Morphine Drugs Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Dosage Form (2021-2033)

12.1.2. Market Revenue and Forecast, by Application (2021-2033)

12.1.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.1.4. Market Revenue and Forecast, by End-use (2021-2033)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Dosage Form (2021-2033)

12.1.5.2. Market Revenue and Forecast, by Application (2021-2033)

12.1.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.1.5.4. Market Revenue and Forecast, by End-use (2021-2033)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Dosage Form (2021-2033)

12.1.6.2. Market Revenue and Forecast, by Application (2021-2033)

12.1.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.1.6.4. Market Revenue and Forecast, by End-use (2021-2033)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Dosage Form (2021-2033)

12.2.2. Market Revenue and Forecast, by Application (2021-2033)

12.2.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.2.4. Market Revenue and Forecast, by End-use (2021-2033)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Dosage Form (2021-2033)

12.2.5.2. Market Revenue and Forecast, by Application (2021-2033)

12.2.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.2.5.4. Market Revenue and Forecast, by End-use (2021-2033)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Dosage Form (2021-2033)

12.2.6.2. Market Revenue and Forecast, by Application (2021-2033)

12.2.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.2.6.4. Market Revenue and Forecast, by End-use (2021-2033)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Dosage Form (2021-2033)

12.2.7.2. Market Revenue and Forecast, by Application (2021-2033)

12.2.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.2.7.4. Market Revenue and Forecast, by End-use (2021-2033)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Dosage Form (2021-2033)

12.2.8.2. Market Revenue and Forecast, by Application (2021-2033)

12.2.8.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.2.8.4. Market Revenue and Forecast, by End-use (2021-2033)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Dosage Form (2021-2033)

12.3.2. Market Revenue and Forecast, by Application (2021-2033)

12.3.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.3.4. Market Revenue and Forecast, by End-use (2021-2033)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Dosage Form (2021-2033)

12.3.5.2. Market Revenue and Forecast, by Application (2021-2033)

12.3.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.3.5.4. Market Revenue and Forecast, by End-use (2021-2033)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Dosage Form (2021-2033)

12.3.6.2. Market Revenue and Forecast, by Application (2021-2033)

12.3.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.3.6.4. Market Revenue and Forecast, by End-use (2021-2033)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Dosage Form (2021-2033)

12.3.7.2. Market Revenue and Forecast, by Application (2021-2033)

12.3.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.3.7.4. Market Revenue and Forecast, by End-use (2021-2033)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Dosage Form (2021-2033)

12.3.8.2. Market Revenue and Forecast, by Application (2021-2033)

12.3.8.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.3.8.4. Market Revenue and Forecast, by End-use (2021-2033)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Dosage Form (2021-2033)

12.4.2. Market Revenue and Forecast, by Application (2021-2033)

12.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.4.4. Market Revenue and Forecast, by End-use (2021-2033)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Dosage Form (2021-2033)

12.4.5.2. Market Revenue and Forecast, by Application (2021-2033)

12.4.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.4.5.4. Market Revenue and Forecast, by End-use (2021-2033)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Dosage Form (2021-2033)

12.4.6.2. Market Revenue and Forecast, by Application (2021-2033)

12.4.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.4.6.4. Market Revenue and Forecast, by End-use (2021-2033)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Dosage Form (2021-2033)

12.4.7.2. Market Revenue and Forecast, by Application (2021-2033)

12.4.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.4.7.4. Market Revenue and Forecast, by End-use (2021-2033)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Dosage Form (2021-2033)

12.4.8.2. Market Revenue and Forecast, by Application (2021-2033)

12.4.8.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.4.8.4. Market Revenue and Forecast, by End-use (2021-2033)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Dosage Form (2021-2033)

12.5.2. Market Revenue and Forecast, by Application (2021-2033)

12.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.5.4. Market Revenue and Forecast, by End-use (2021-2033)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Dosage Form (2021-2033)

12.5.5.2. Market Revenue and Forecast, by Application (2021-2033)

12.5.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.5.5.4. Market Revenue and Forecast, by End-use (2021-2033)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Dosage Form (2021-2033)

12.5.6.2. Market Revenue and Forecast, by Application (2021-2033)

12.5.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.5.6.4. Market Revenue and Forecast, by End-use (2021-2033)

Chapter 13. Company Profiles

13.1. Pfizer Inc.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Sun Pharmaceutical Industries Ltd.

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Verve Health Care Ltd.

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Mallinckrodt Pharmaceuticals

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Purdue Pharma

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Qinghai Pharmaceuticals

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. AbbVie Inc.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers
Ask to Expert